Eli Lilly and

Yahoo Finance • 10 hours ago

Eli Lilly (LLY) Moves Fast to Secure Lead in India’s Obesity Drug Market

Eli Lilly and Company (NYSE:LLY) is included among the 14 Best Pharma Dividend Stocks to Buy in 2026.Eli Lilly (LLY) Moves Fast to Secure Lead in India’s Obesity Drug Market Eli Lilly and Company (NYSE:LLY) is moving quickly to lock in it... Full story

Yahoo Finance • 12 hours ago

Dow Jones Futures: Market Holds Near Highs With 2025 Ending; Eli Lilly, Shopify Forge New Buy Points

The stock market will enter the final day of 2025 near highs — and key support. Shopify, Eli Lilly have forged new buy points. Continue Reading... Full story

Yahoo Finance • 16 hours ago

Eli Lilly and Novo Nordisk Shares Dip After Cut Obesity Drug Prices in China

This article first appeared on GuruFocus. Novo Nordisk (NYSE:NVO) and Eli Lilly (NYSE:LLY) saw their shares dip about 0.5% on Tuesday after the companies lowered prices for their obesity treatments in China. The Danish pharmaceutical com... Full story

Yahoo Finance • 18 hours ago

Should You Buy the iShares S&P 500 ETF Before 2026, Even With the Stock Market at an All-Time High?

Key Points The S&P 500 is a diversified index featuring 500 stocks from 11 different economic sectors. The index has delivered a compound annual return of 10.5% since its inception in 1957. The iShares Core S&P 500 ETF is a very low-cost... Full story

Yahoo Finance • 19 hours ago

Novo Nordisk and Eli Lilly Slash Obesity Drug Prices in China

This article first appeared on GuruFocus. Novo Nordisk (NOVO, Financials) and Eli Lilly (LLY, Financials) are reducing prices for their leading obesity treatments, Wegovy and Mounjaro, in China to strengthen market share in the world's mo... Full story

Yahoo Finance • 22 hours ago

Novo and Lilly cut prices of weight-loss drugs in China

STORY: Novo Nordisk and Eli Lilly are lowering prices of their top-selling obesity drugs Wegovy and Mounjaro in China.Novo did not give details on the new prices.But media outlet Yicai reported earlier that list prices for the two highest... Full story

Yahoo Finance • yesterday

Best Weight Loss Pills for 2026? FDA Approves First Oral GLP-1 as Patients Evaluate Wegovy, Zepbound, and Telehealth Access Pathways

Newark, DE, Dec. 29, 2025 (GLOBE NEWSWIRE) -- The term "best" reflects common consumer search phrasing and is used here to explore access pathways and evaluation criteria, not to endorse or rank any specific product or provider. This ana... Full story

Yahoo Finance • 2 days ago

CMS unveils payment model to boost GLP-1 access for Medicare Part D, Medicaid

[Two packages of 5 dosing pens each of a fictitious Semiglutin drug used for weight loss (antidiabetic medication or anti-obesity medication) on a blue transparent background. Fictitious package design] aprott * CMS has unveiled a volun... Full story

Yahoo Finance • 2 days ago

UnitedHealth Works Toward Recovery and 4 More Healthcare Themes to Watch in 2026

Much in the new year depends on the fundamentals, which remain as complicated as ever. Watch these stocks. Continue Reading... Full story

Yahoo Finance • 2 days ago

This Beaten-Down Stock Just Jumped By 8%. Time to Buy?

Key Points Pharmaceutical giant Novo Nordisk just earned approval for an oral version of Wegovy. This could help improve its position in the increasingly competitive weight loss market. Despite some headwinds, there are several reasons to... Full story

Yahoo Finance • 2 days ago

The Obesity Pill Rush: Healthcare ETFs to Gain as FDA Nods to Novo Drug

The recent U.S. Food and Drug Administration (FDA) approval of Novo Nordisk’s NVO oral obesity pill, Wegovy, marks a significant turning point in the fiercely competitive weight-loss drug market. This pill, the first GLP-1 tablet specifica... Full story

Yahoo Finance • 2 days ago

The Weight Loss Drug Competition Is Heating Up: These 2 Industry Leaders Just Filed Competing Drugs with the FDA.

Key Points Novo Nordisk's CagriSema could be a brand new growth driver for the company. Eli Lilly's orforglipron is breaking into a new, lucrative market. One of these companies should lead this market, but both could be attractive buys.... Full story

Yahoo Finance • 5 days ago

Sector Update: Health Care Stocks Edge Higher Late Afternoon

Health care stocks were edging up late Friday afternoon with the NYSE Health Care Index and the Stat PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 5 days ago

Sector Update: Health Care Stocks Lower in Friday Afternoon Trading

Health care stocks declined Friday afternoon, with the NYSE Health Care Index and the State Street H PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 5 days ago

GLP-1 Drugs Quietly Reshape How Americans Shop for Food, Study Finds

This article first appeared on GuruFocus. Weight loss may be just one side effect of GLP-1 drugs. A new study suggests they're also changing how consumers spend on food. Researchers at Cornell University's SC Johnson College of Business... Full story

Yahoo Finance • 5 days ago

Lilly and Novo Cut GLP-1 Prices as Pill Approvals Expand Access

This article first appeared on GuruFocus. Weight-loss drugs known as GLP-1s are increasingly reshaping healthcare and the pharmaceutical landscape, with Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO) emerging as the two dominant forces... Full story

Yahoo Finance • 5 days ago

ABL Bio Receives Upfront Payment for License, Research and Collaboration Agreement for Grabody Platform and Equity Investment from Lilly

- Secured a total of 55 million in R&D funding, including 40 million in upfront payment and 15 million in equity investment - Accelerating R&D on core technologies, including expansion of indications for the Grabody platform SEOUL, South... Full story

Yahoo Finance • 6 days ago

Is Eli Lilly Pulling Ahead in the Weight Loss Drug Battle?

Key Points Eli Lilly is the clear leader in the burgeoning weight loss market. Its lineup and pipeline put it well ahead of even its closest competitor. The drugmaker should continue riding this wave for the foreseeable future. 10 stocks... Full story

Yahoo Finance • 6 days ago

Novo, Lilly race to cement lead in India’s obesity drug market, Reuters says

Eli Lilly (LLY) and Novo Nordisk (NVO) are racing to cement their lead in India’s obesity drug market before cheaper generic version enter stores in March, Rishika Sadam of Reuters reports. Novo’s strategy focuses on price cuts and acceler... Full story

Yahoo Finance • 6 days ago

Viking Therapeutics (VKTX) Is Up 8.9% After Rival Data Bolsters Its Oral Obesity Program

In recent days, analyst Joseph Pantginis of H.C. Wainwright reaffirmed a positive stance on Viking Therapeutics after competitor Eli Lilly’s successful Phase 3 oral obesity study appeared to support Viking’s own oral obesity drug program.... Full story